Savara Inc. has released a corporate presentation detailing its ongoing efforts to develop new therapies for rare respiratory diseases, with a particular focus on autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The company highlighted the challenges faced by patients, including frequent misdiagnosis and the current reliance on whole lung lavage as the primary treatment option. Savara is advancing MOLBREEVI (molgramostim inhalation solution), which has been conditionally accepted as a trade name by the FDA and EMA, though it is not yet approved for any indication. The company plans to resubmit its Biologics License Application (BLA) in December 2025. The executive leadership team, including CEO Matthew Pauls, is overseeing these initiatives. You can access the full presentation through the link below.